Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients

被引：0
|
作者：
Chee M. Ng
A. Patnaik
M. Beeram
C. C. Lin
C. H. Takimoto
机构：
[1] Cancer Therapy and Research Center,Institute for Drug Development
[2] South Texas Accelerated Research Therapeutics (START),Department of Oncology
[3] Children Hospital of Philadelphia,undefined
[4] National Taiwan University Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Troxacitabine; Pharmacokinetics; Pharmacodynamics; Model; Phase I study; Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：985 / 994
页数：9
相关论文
共 50 条
  • [1] Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Ng, Chee M.
    Patnaik, A.
    Beeram, M.
    Lin, C. C.
    Takimoto, C. H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 985 - 994
  • [2] Semi-physiological pharmacokinetic-pharmacodynamic (PK/PD) models for troxacitabine-induced neutropenia and thrombocytopenia
    Ng, C. M.
    Muralidhar, B.
    Takimoto, C. H.
    Lin, C.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] ANALYZING COMPLEX POPULATION PHARMACOKINETIC/PHARMACODYNAMIC DATA USING NOVEL MCPEM-SAEM ALGORITHM IN S-ADAPT: TROXACITABINE-INDUCED NEUTROPENIA IN CANCER PATIENTS.
    Ng, C. M.
    Takimoto, C. H.
    Bauer, R. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S8 - S9
  • [4] Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
    Sukumaran, Siddharth
    Gadkar, Kapil
    Zhang, Crystal
    Bhakta, Sunil
    Liu, Luna
    Xu, Keyang
    Raab, Helga
    Yu, Shang-Fan
    Mai, Elaine
    Fourie-O'Donohue, Aimee
    Kozak, Katherine R.
    Ramanujan, Saroja
    Junutula, Jagath R.
    Lin, Kedan
    PHARMACEUTICAL RESEARCH, 2015, 32 (06) : 1884 - 1893
  • [5] Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
    Siddharth Sukumaran
    Kapil Gadkar
    Crystal Zhang
    Sunil Bhakta
    Luna Liu
    Keyang Xu
    Helga Raab
    Shang-Fan Yu
    Elaine Mai
    Aimee Fourie-O’Donohue
    Katherine R. Kozak
    Saroja Ramanujan
    Jagath R. Junutula
    Kedan Lin
    Pharmaceutical Research, 2015, 32 : 1884 - 1893
  • [6] Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia
    Hing, J.
    Perea-Ruixo, J. J.
    Stuyckens, K.
    Soto-Matos, A.
    Lopez-Lazaro, L.
    Zannikos, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) : 130 - 143
  • [7] Mechanism-based pharmacokinetic - Pharmacodynamic modeling of bendazac lysine
    Luo, Jianping
    Yu, Junxian
    Zhang, Yindi
    Chen, Xaoxiang
    Shen, Jianping
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 204 - 204
  • [8] Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
    Harrold, John M.
    Abraham, Anson K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 (02) : 141 - 151
  • [9] Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
    John M. Harrold
    Anson K. Abraham
    Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41 : 141 - 151
  • [10] Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects
    David Czock
    Frieder Keller
    Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34 : 727 - 751
12345